Fabio Cataldi

Appearances

EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
Date
May 20, 2024
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
Presenter
Evan Dellon
University of North Carolina School of Medicine
Speakers
Margaret Collins
Arjan Bredenoord
Amsterdam UMC, University of Amsterdam
Hamish Philpott
Luc Biedermann
Márjori Dulcine
Thai Nguyen-Cleary
Chinyu Su
Jin Yu
Huaming Tan
Fabio Cataldi
Hanzhe Zheng
Wenjin Wang
Pamela Clax
John Woolcott
Ikuo Hirano